Are you Dr. Magnifico?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 97 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 Kennedy Dr
Torrington, CT 06790Phone+1 860-482-5384Fax+1 860-496-4951
Summary
- Dr. Michael Magnifico, MD is an oncologist in Torrington, Connecticut. He is currently licensed to practice medicine in Connecticut. He is affiliated with Charlotte Hungerford Hospital and Sharon Hospital.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1982- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1978 - 1979
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1977 - 1978- New York Presbyterian Hospital (Columbia Campus)Residency, Pathology-Anatomic and Clinical, 1976 - 1977
- New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1975 - 1976
Columbia University Vagelos College of Physicians and SurgeonsClass of 1975
Certifications & Licensure
CT State Medical License 1979 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
- A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsRetroperitoneal mass presentations of B-immunoblastic sarcoma.James A. Waldron, Michael Magnifico, Paul H. Duray, Ed Cadman
Cancer. 1985-10-01
Professional Memberships
- Member
